Chiasma, Inc. (CHMA) EPS Estimated At $-0.31 on March, 19

Chiasma, Inc. (NASDAQ:CHMA) Corporate Logo

Investors wait Chiasma, Inc. (NASDAQ:CHMA)’s quarterly earnings on March, 19., Faxor reports. EPS of $-0.31 is 47.62 % down from 2018’s $-0.21 EPS. 0.00 % EPS growth is what Wall Street’s sees after $-0.31 reported EPS last quarter. CHMA is touching $6.93 during the last trading session, after increased 3.90%.Chiasma, Inc. is uptrending after having risen 206.45% since March 14, 2018. CHMA has 303,215 volume or 223.18% up from normal. CHMA outperformed by 202.08% the S&P500.

Chiasma, Inc. (NASDAQ:CHMA) Ratings Coverage

Total analysts of 2 have positions in Chiasma (NASDAQ:CHMA) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since February 14, 2019 according to StockzIntelligence Inc Chiasma has 4 analyst reports. The stock rating was initiated by Roth Capital with “Buy” on Tuesday, February 19. On Friday, March 8 the rating was maintained by H.C. Wainwright with “Buy”.

Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies using transient permeability enhancer technology platform.The firm is worth $169.55 million. The firm offers octreotide capsules, which is in Phase III clinical trial for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone under the MYCAPSSA name.Last it reported negative earnings.

For more Chiasma, Inc. (NASDAQ:CHMA) news published briefly go to: Benzinga.com, Seekingalpha.com, Benzinga.com, Globenewswire.com or Benzinga.com. The titles are as follows: “58 Biggest Movers From Yesterday – Benzinga” published on March 07, 2019, “UBS sees 38% upside for Teva in permarket analyst action – Seeking Alpha” on March 07, 2019, “56 Stocks Moving In Tuesday’s Mid-Day Session – Benzinga” with a publish date: March 05, 2019, “Chiasma to Participate in Three Investor Conferences in March – GlobeNewswire” and the last “The Daily Biotech Pulse: Allergan’s Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO – Benzinga” with publication date: March 07, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.